Titer Data of TurboCHO™ Stable Cell Pool & Cell Line
Stable CHO-K1 cell pools/lines are commonly created using recombinant DNA technology, where a foreign gene is introduced into the cells, and selective pressure is applied to enrich for cells that have incorporated and stably express the foreign gene. This approach offers several advantages over transient expression systems, including consistent protein supply, reduced variability between batches, and scalability to industrial levels. However, some next-generation biotherapeutics are difficult to express at desired quantities in CHO cells, which led to the establishment of the TurboCHO™ stable cell pool/cell line expression platform by GenScript. This platform, coupled with AI-powered GenSmart™ codon optimization system and optimized fed-batch culture process, provides high expression levels for high-quality recombinant protein/antibody with fast turnaround times. The expression results are comparable with the TurboCHO™ transient expression platform (TurboCHO™ HT & TurboCHO™ Express), offering more flexible choices from small to large scale during the discovery timeline.
High Expression Level
Average expression level (Fc-related antibody): Cell pool: 1.6~2.0 g/L; Cell line: 2.7~3.0 g/L
License-Agreed Cell
ECACC-licensed CHO-K1 cell
Flexible payments based on milestones
High-Quality Products
High purity antibodies
Customized QC tests
| Service Details | Timeline | Deliverables |
|---|---|---|
| Phase I: Plasmid & Cell line preparation | ||
| Codon optimization & plasmid construction | 2 wks | Top clones/pools (2 vials, 1×107 cells/ml, 1mL/vial) |
| Stable cell pool generation (including transfection, screening, selection) | 8 wks | |
| Stable cell line generation (including transfection, screening, single clone selection and cryopreservation) (optional) | 4-6 wks | |
| Fed-batch culture and expression titer (for IgG-like antibodies and Fc-fusion proteins) determination, QC for cell pool/line | 2 wks | Report with mycoplasma test and expression titer |
| Phase II: Scale-up expression and purification | ||
| 1L fed-batch cell expression & one-step purification | 2-3 wks |
|
| Option: N liter fed-batch cell expression & one-step purification | Depends on scale |
|
Note:
1. GenScript will cryopreserve 2 vials of the top stable cell line for further
scaling-up (excluding the
cell stocks to be delivered) for 12 months with no extra charge. GenScript offers an
optional extension
package of storage service for frozen cell stocks.
2. Developed cell lines and proteins produced by corresponding cells in this proposal are limited to
Research Use. A new license agreement is needed if the client would like
to use the developed cell line and
produced proteins for commercial purposes.
Titer Data of TurboCHO™ Stable Cell Pool & Cell Line
Human IgG1 Antibody Production, Expression Titer: 1749 mg/L; Purity (SDS-Page): >95%; Purity (SEC-HPLC): >99%
Rabbit IgG Antibody Production, Final Yield: 1380 mg/L; Purity (SDS-Page): >95%; Purity (SEC-HPLC): >99%
mIgG2a-scFv Antibody Production, Final Yield: 882 mg/L; Purity (SDS-Page): >95%; Purity (SEC-HPLC): >99%
Recombinant His-Protein Production, Final Yield: 493 mg/L; Purity (SDS-Page): >90%; Purity (SEC-HPLC): >93%
The importance of protein expression in antibody drug discovery.
The progress of CHO cell line development.
How GenScript TurboCHO platform provides protein/antibody expression services for antibody drug discovery solutions.
Learn MoreOverview of recombinant therapeutic antibody
Host selection for recombinant antibody expression
Why CHO expression system is still the favorable workhorse for recombinant protein production
Learn MoreFrom gene synthesis to protein delivery as fast as 8 BDs
Learn MoreDesigned for high-throughput screening, as fast as 2 weeks
Learn MoreYield up to gram, from 3 weeks
Learn MoreYield up to kg, from 6-7 weeks
Learn MoreCellPower™ for drug discovery, toxicity testing and basic research
Learn More
